EGFR and neoplasm: Thus, while our data suggest that negative hyperselection status may be more informative for treatment selection than tumor sidedness, further investigations are necessary to confirm whether anti-EGFR antibody therapy is truly beneficial for negatively hyperselected patients with right-sided mCRC.